Global Hemophilia Market Report: 2016 Edition - New Report by Koncept Analytics - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Global Hemophilia Market Report: 2016 Edition - New Report by Koncept Analytics

Description:

The global hemophilia market report provides a comprehensive study of global hemophilia market and also major regional markets. For more mail: vikas@konceptanalytics.com – PowerPoint PPT presentation

Number of Views:28

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Global Hemophilia Market Report: 2016 Edition - New Report by Koncept Analytics


1
Global Hemophilia Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details
  • Executive Summary
  • Hemophilia refers to a set of hereditary genetic
    disorders that impairs the body's ability to
    control blood clotting, which controls bleeding
    when a blood vessel is broken. People with
    hemophilia lack, either partially or completely,
    an essential clotting factor needed to form
    stable blood clots. In the absence of a
    treatment, uncontrolled internal bleeding can
    occur, causing stiffness, pain, severe joint
    damage and even death. Depending upon the
    coagulation factor deficiency, there are
    different types of hemophilia such as Hemophilia
    A, Hemophilia B, Hemophilia C, Von Willebrand
    disease and Hemophilia with Inhibitors.
  • Even though Hemophilia is rare bleeding disorder,
    the number of people affected by it has been
    increasing with time. While mild hemophilia is
    easy to diagnose especially in kids, when they
    learn to move and walk, and get large bruises
    from minute falls, severe hemophilia patients
    need to go for periodic transfusion of the
    respective factors so as to avoid the event of
    life-threatening bleeding episodes. Such a
    periodic transfusion is done through what is
    commonly known as the replacement therapy. With
    increasing sophistication and modernization of
    technology, demand for advanced treatment options
    increases, thereby making the entire market grow.
  • The key factors which are anticipated to drive
    this market include increasing penetration of
    recombinant factor VIII, increasing healthcare
    expenditure, emerging use of treatments in low
    income countries and increasing diagnosis rates.
    Some of the noteworthy progresses of this
    industry include the increasing adoption of
    prophylaxis therapy, introduction of extended
    half-life products and gene therapy. However, the
    growth of respective industry is challenged by
    the high cost of treatments and high reluctance
    by patients to switch to new treatments/products.
  • The report provides a comprehensive study of
    global hemophilia market and also major regional
    markets. Furthermore, market dynamics such as key
    trends and development and challenges are
    analyzed in depth. The global hemophilia industry
    is highly competitive consisting of several large
    companies including the Shire Plc, Bayer Group,
    Pfizer Inc, Novo Nordisk etc. The competitive
    landscape of the respective market, along with
    the company profiles of the leading players are
    also discussed in detail.

3
Even though Hemophilia is a rare bleeding
disorder, the number of people affected by it has
been increasing with time.
Global Hemophilia Prevalence (2015)
  • In the year 2015, it is recorded that the total
    number of people affected by hemophilia across
    the globe, accounts to xx thousand persons
  • The global hemophilia market revenue, excluding
    the revenue for Von Willebrand disease, for the
    year 2015 is estimated to be USxx.x billion.
  • It is forecasted that the demand for prophylaxis
    FVIII will rise at a CAGR of x.xx over the
    period 2015-2017, while the demand for
    recombinant FVIII will rise at a CAGR of xx.x
    over the same period, amounting to xx billion
    units and xx billion units respectively, by the
    end of 2017.

Global Hemophilia Market Revenue (2015E-2020F)
Global FVIII Demand by Category - Volume
(2015E-2017E)
4
Due to increased use of prophylaxis in the US, as
well as pharmaceutical companies expansion of
markets, the US hemophilia market revenue has
witnessed a steady growth over time
The US Hemophilia Patients Treated per Year
(2013-2020F)
  • The number of persons treated in the year 2015 is
    estimated to be xxx thousand, rising from xxx
    thousand in the previous year. Further, it is
    forecasted that this number of hemophilia
    patients treated will rise at a CAGR of x.xx
    over the period spanning 2016-2020.
  • The US hemophilia A market revenue is estimated
    to have risen from USxxx billion in 2014 to
    USxxx3 billion in 2015, with a YoY change of
    xx. It is forecasted that the revenue will rise
    further in future at a CAGR of xx during the
    five year period spanning 2016-2020, recording
    USxxx1 billion in 2020F.
  • It is estimated that the revenue for 2015 has
    increased to USxxx.xx million, from US551 xxx.x
    to grow at a CAGR of xx during the period
    spanning 2016-2020, amounting to nearly USxxx
    million in 2020.

The US Hemophilia B Market Revenue (2013-2020F)
The US Hemophilia A Market Revenue (2013-2020F)
5
Recombinant FVIII has significantly higher use in
developed countries, whereas emerging markets
witness an increasing acceptance as they develop.
The US Von Willebrand Factor Market Revenue
(2013-2020F)
  • The US Von Willebrand factor revenue is estimated
    to have grown from USxxx million in 2014 to
    USxxx million in 2015 and is forecasted to grow
    further at a CAGR of xx.2 over the period
    2016-2020, amounting to USxxx million in the
    year 2020F.
  • The number of hemophilia A patients in Europe is
    estimated to have risen from xx thousand persons
    in 2014 to xx persons in 2015, with a YoY rise of
    xx.x5.
  • It is estimated that there were nearly xxx
    thousand patients of hemophilia B in Europe in
    2015 and it is forecasted that with the number of
    patients in this segment will reach nearly xxx.x
    thousand by the year 2020.

Europe Hemophilia B Patients (2015E-2020F)
Europe Hemophilia A Patients (2014-2020F)
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Hemophilia Market . To know more about this
report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com
About PowerShow.com